Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.

Clinical therapeutics - 1 Dec 2013

Almeida Luis, Nunes Teresa, Costa Raquel, Rocha José F, Vaz-da-Silva Manuel, Soares-da-Silva Patricio

Abstract excerpt

BACKGROUND: Etamicastat is a dopamine β-hydroxylase (DβH) inhibitor currently in clinical development for the treatment of hypertension and heart failure. OBJECTIVE: This study assessed the tolerability, pharmacokinetics, and pharmacodynamics of etamicastat in patients with arterial hypertension. METHODS: This randomized, double-blind, placebo-controlled study was conducted in male patients aged between 18 and 65...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzopyrans

Share to Blood Pressure Monitoring, Ambulatory

Share to Dopamine beta-Hydroxylase

Share to Double-Blind Method

Share to Heart Rate

Share to Imidazoles

Source

Identifiers

PMID: 24296323
DOI: 10.1016/j.clinthera.2013.10.012

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.PMID 24296323Read ↗

Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.Semantic proximity Read ↗

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.Semantic proximity Read ↗

Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.Semantic proximity Read ↗

Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.Semantic proximity Read ↗

Genotype-Guided Hydralazine TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.Semantic proximity Read ↗

Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N-Acetyltransferase NAT2.Semantic proximity Read ↗

N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes.Semantic proximity Read ↗

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.Semantic proximity Read ↗

Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.Semantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.Semantic proximity Read ↗

Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.